Mineralys Therapeutics, Inc. MLYS Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s common stock?
- Mineralys Therapeutics, Inc. (MLYS) reported common stock of 500M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s common stock changed year-over-year?
- Mineralys Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 500M to 500M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s common stock has grown at a 16.2% compound annual growth rate (CAGR), from 319M to 500M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).